Pharmaceutical Kitting Automation: Use Cases, Requirements, and Rollout

A pharmaceutical kit can have every component in the right slot and still be unusable. If nobody can show which lot of each component went into which kit, who verified it, and how it was stored, the kit fails review. In pharma and healthcare distribution, kitting is a traceability job first and a handling job second.

This guide covers common kit types, the traceability and verification requirements that shape them, what to evaluate in pharmaceutical kitting automation, and how to roll it out without putting your quality system at risk. For a comparison of kitting technologies in general, see our robotic kitting systems guide. This page is a practical overview, not legal or regulatory advice.

Common pharmaceutical and healthcare kit types

• Patient kits. Starter or titration kits and patient support program kits that pair product with instructions, devices, or accessories.

• Sample kits. Drug samples and supporting materials for distribution programs. Federal rules on drug samples in 21 CFR part 203, subpart D include a section on fulfillment houses and mailing services, and require manufacturers and authorized distributors of record to put a lot or control number on the sample unit label and its outer packaging.

• Clinical supply kits. Investigational product packed to a study protocol, often with kit numbers for blinding. The immediate package of an investigational new drug intended for human use must carry the caution statement in 21 CFR 312.6 limiting it to investigational use.

• Ancillary and procedure kits. Non-drug supplies such as syringes, swabs, and pads packed for clinics, home infusion, or trial sites.

Kit types differ in who owns the regulatory decision. Before you automate, confirm with quality and regulatory affairs which activities at your site count as packaging or labeling of drug product, and which are warehousing and distribution.

Traceability: lots, serials, and DSCSA

The Drug Supply Chain Security Act sets out steps toward an interoperable, electronic way to identify and trace certain prescription drugs at the package level as they move through the supply chain. Three points matter most for kitting.

• The product identifier. FDA's product identifier guidance describes it as the standardized numerical identifier (the NDC plus a serial number), lot number, and expiration date, in human-readable and machine-readable form. Packages carry it in a 2D data matrix barcode; homogeneous cases use a linear or 2D data matrix barcode.

• Dates. FDA exempted eligible trading partners from the enhanced, package-level electronic tracing requirements until May 27, 2025 for manufacturers and repackagers, August 27, 2025 for wholesale distributors, and November 27, 2025 for dispensers with 26 or more full-time employees licensed as pharmacists or qualified as pharmacy technicians. Those periods have ended. FDA has exempted small dispensers from certain requirements until November 27, 2027, and other trading partners that cannot comply can request a waiver, exception, or exemption.

• 3PLs. Third-party logistics providers must be licensed and report licensure and other information to FDA annually to be authorized trading partners.

What this means on the kitting floor

• When a kit contains a serialized package, capture that package's serial, lot, and expiry in the kit record at the moment of placement.

• Do not let labels, inserts, or tray design cover a package's barcode if it needs to be scanned downstream.

• Placing a sealed package into a kit and opening that package are different activities. Confirm the obligations with regulatory affairs before any automated step opens, relabels, or repacks drug product.